HER2 Targeting Therapies

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the HER2 targeting therapies market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to various aspects of cancer immunotherapy. The chapter lays emphasis on the role of targeting therapies in cancer treatment, including details on the HER2 mutations, mechanism of action of HER2 targeting therapies and the type of molecules that are developed / being developed. Further, it includes a discussion on the various challenges associated with the use of HER2 targeting therapies and highlights certain future perspectives.

Chapter 4 provides an overview of more than 200 molecules that are currently under development for the treatment of various cancer indications, along with a detailed analysis of these molecules, based on phase of development (marketed, clinical, preclinical and discovery stage) of lead candidates, type of molecule (biologic and small molecule), type of biologic (antibody drug conjugates, bispecific antibodies, CAR-T cell therapies, monoclonal antibodies, vaccines and others), type of therapy (monotherapy, combination therapy and both), target disease indication(s),  therapeutic area(s) and route of administration (intradermal, intravenous, oral, and others). In addition, the chapter provides information on drug developer(s), highlighting their year of establishment, company size and geographical location of headquarters.

Chapter 5 includes detailed profiles of the key players (shortlisted based on number of pipeline products) engaged in the development of HER2 targeting therapies. Each profile includes a brief overview of the company, details on its product portfolio, and recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of more than 1,500 completed, ongoing and planned clinical studies of HER2 targeting therapies, based on the parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, target indication(s), focus areas, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 7 provides an analysis of more than 1,300 grants awarded to research institutes engaged in the projects related to HER2 targeting therapies, in the period between 2018 and 2021 (till March) based on important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, focus area, prominent program officers, and recipient organizations.

Chapter 8 features a detailed analysis of the various partnerships and collaborations that have been established amongst the stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, and other agreements) adopted by stakeholders. It also includes analysis of the key companies that have established maximum number of partnerships, highlighting most popular type of molecule, and target disease indications.

Chapter 9 includes an insightful market forecast analysis, presenting the likely growth of HER2 targeting therapies market till the year 2031. In addition, we have provided inputs on the likely distribution of the market opportunity based on different target indications (breast cancer, gastric cancer, head and neck cancer and lung cancer), type of molecule (small molecule and biologic), type of therapy (monotherapy, combination therapy and both), route of administration (intravenous and oral) and key geographical regions (US, Europe, Asia-Pacific, Middle East and North Africa and Latin America). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 10 presents a case study on HER2 targeting biosimilars, highlighting market landscape of various biosimilars molecules that are developed / being developed. These molecules are further analyzed on the basis of several parameters, such as parent drug, phase of development and target disease indications. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.

Chapter 11 features a case study on companion diagnostic tests for that are developed / being developed corresponding to various HER2 targeting drug candidates, and their analysis on the basis of their commercial availability, assay technique used, corresponding drug candidate and target disease indication. This chapter also provide insights on developer landscape, including information on year of establishment and geographical location of headquarters of the companies.

Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the HER2 targeting therapies market.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. HER2 Mutations
3.5. Overview of HER2 Targeting Therapies
3.5.1 Biologics Targeting HER2
3.5.1.1 Types of Products
3.5.2 Small Molecules Targeting HER2
3.5.2.1 Types of Products
3.6. Existing Challenges and Future Perspectives

4. CURRENT MARKET LANDSCAPE: MARKETED PRODUCTS AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. HER2 Targeting Therapies: Marketed Products and Development Pipeline

4.3. HER2 Targeting Therapies: Pipeline Analysis
4.3.1. Analysis by Current Status
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Route of Administration
4.3.8. Analysis by Phase of Development and Type of Molecule
4.3.9. Analysis by Phase of Development and Route of Administration

4.4. HER2 Targeting Therapies: Developer Landscape
4.4.1. Analysis by Type of Developer
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Geographical Location
4.4.5. Analysis by Company Size and Geographical Location
4.4.6. Leading Industry Players: Analysis by Number of Therapies
4.4.7. Leading Non-Industry Players: Analysis by Number of Therapies

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AstraZeneca
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. HER2 Targeting Therapies Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Boehringer Ingelheim
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. HER2 Targeting Therapies Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. GlaxoSmithKline
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. HER2 Targeting Therapies Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. MacroGenics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. HER2 Targeting Therapies Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Pfizer
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. HER2 Targeting Therapies Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Puma Biotechnology
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. HER2 Targeting Therapies Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Roche
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. HER2 Targeting Therapies Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. Seagen (previously Seattle Genetics)
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. HER2 Targeting Therapies Portfolio
5.9.4. Recent Developments and Future Outlook

5.10. Triumvira Immunologics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. HER2 Targeting Therapies Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Zymeworks
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. HER2 Targeting Therapies Portfolio
5.11.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS 
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. HER2 Targeting Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase and Enrolled Patient Population
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Sponsor / Collaborator
6.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Disease Indication
6.3.10. Analysis by Target Therapeutic Area 
6.3.11. Geographical Analysis by Number of Registered Trials 
6.3.12. Geographical Analysis by Enrolled Patient Population 

7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. ` Scope and Methodology

7.3. HER2 Targeting Therapies: Analysis of Awarded Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Word Cloud Analysis: Emerging Focus Areas
7.3.10. Analysis by Study Section Involved
7.3.11. Popular NIH Departments: Analysis by Number of Grants Awarded
7.3.12. Prominent Program Officers: Analysis by Number of Grants Awarded
7.3.13. Analysis by Type of Recipient Organization
7.3.14. Popular Recipient Organizations: Analysis by Number of Grants Awarded
7.3.15. Regional Distribution of Recipient Organizations

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models

8.3. HER2 Targeting Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships

8.4. Regional Analysis
8.4.1. Intercontinental and Intracontinental Agreements

9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global HER2 Targeting Therapies Market, 2021-2031
9.4. HER2 Targeting Therapies: Individual Product Sales Forecasts 
9.4.1. BAT8001 (Bio-Thera Solutions)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast

9.4.2. ENHERTU® (AstraZeneca)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast

9.4.3. Gilotrif® (Boehringer Ingelheim)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast

9.4.4. KADCYLA™ (Roche)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast

9.4.5. MARGENZA™ (MacroGenics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast

9.4.6. RC48 (RemeGen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast

9.4.7. Nerlynx™ (Puma Biotechnology)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast

9.4.8. Perjeta® (Genentech, a Roche’s company)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast

9.4.9. SYD985 (Byondis)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast

9.4.10. MOBOCERTINIB (Takeda)
9.4.10.1. Target Patient Population
9.4.10.2. Sales Forecast

9.4.11. Tukysa® (Seagen)
9.4.11.1. Target Patient Population
9.4.11.2. Sales Forecast

9.4.12. Tyverb® (Roche)
9.4.12.1. Target Patient Population
9.4.12.2. Sales Forecast

9.4.13. Vizimpro® (Pfizer)
9.4.13.1. Target Patient Population
9.4.13.2. Sales Forecast

9.5. Global HER2 Targeting Therapies Market, 2021-2031: Distribution by Geography
9.5.1. HER2 Targeting Therapies Market in the North America, 2021-2031
9.5.2. HER2 Targeting Therapies Market in Europe, 2021-2031
9.5.3. HER2 Targeting Therapies Market in Asia Pacific, 2021-2031
9.5.4. HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031
9.5.5. HER2 Targeting Therapies Market in Latin America, 2021-2031

9.6. Global HER2 Targeting Therapies Market: Distribution by Target Disease Indication
9.6.1. Global HER2 Targeting Therapies Market for Breast Cancer, 2021-2031
9.6.2. Global HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031
9.6.3. Global HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031
9.6.4. Global HER2 Targeting Therapies Market for Lung Cancer, 2021-2031
 
9.7. Global HER2 Targeting Therapies Market: Distribution by Type of Molecule
9.7.1. Global HER2 Targeting Therapies Market for Biologics, 2021-2031
9.7.2. Global HER2 Targeting Therapies Market for Small Molecules, 2021-2031

9.8. Global HER2 Targeting Therapies Market: Distribution by Type of Therapy
9.8.1. Global HER2 Targeting Therapies Market for Monotherapy, 2021-2031
9.8.2. Global HER2 Targeting Therapies Market for Combination Therapy, 2021-2031
9.8.3. Global HER2 Targeting Therapies Market for Both Therapies, 2021-2031

9.9. Global HER2 Targeting Therapies Market: Distribution by Route of Administration
9.9.1. Global HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031
9.9.2. Global HER2 Targeting Therapies Market for Oral Therapies, 2021-2030

10. CASE STUDY: HER2 TARGETING BIOSIMILARS
10.1. Chapter Overview
10.2. HER2 Targeting Biosimilars: Marketed Products and Development Pipeline
10.3. HER2 Targeting Biosimilars: Pipeline Analysis
10.3.1. Analysis by Parent Drug
10.3.2. Analysis by Phase of Development of Biosimilar
10.3.3. Analysis by Target Disease Indication

10.4. HER2 Targeting Biosimilars: Developer Landscape
10.4.1. Analysis by Year of Establishment
10.4.2. Analysis by Geographical Location
10.4.3. Analysis by Company Size and Geographical Location

11. CASE STUDY: COMPANION DIAGNOSTICS FOR HER2 TARGETING THERAPIES
11.1. Chapter Overview
11.2. Companion Diagnostics for HER2 Targeting Therapies
11.2.1. Analysis by Commercial Availability of the Test
11.2.2. Analysis by Assay Technique Used
11.2.3. Analysis by Corresponding Drug Candidate
11.2.4. Analysis by Target Disease Indication

11.3. Companion Diagnostics for HER2 Targeting Therapies: Developer Overview
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geographical Location

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 HER2 Signaling Pathway
Figure 4.1 HER2 Targeting Therapies: Distribution by Current Status
Figure 4.2 HER2 Targeting Therapies: Distribution by Phase of Development
Figure 4.3 HER2 Targeting Therapies: Distribution by Type of Molecule
Figure 4.4 HER2 Targeting Therapies: Distribution by Type of Biologic
Figure 4.5 HER2 Targeting Therapies: Distribution by Type of Therapy
Figure 4.6 HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 4.7 HER2 Targeting Therapies: Distribution by Route of Administration
Figure 4.8 HER2 Targeting Therapies Developers: Distribution by Type of Developer
Figure 4.9 HER2 Targeting Therapies Developers: Distribution by Year of Establishment
Figure 4.10 HER2 Targeting Therapies Developers: Distribution by Company Size
Figure 4.11 HER2 Targeting Therapies Developers: Distribution by Geographical Location
Figure 4.12 HER2 Targeting Therapies Developers: Distribution by Company Size and Geographical Location
Figure 4.13 Leading Industry Players: Distribution by Number of Pipeline Candidates
Figure 4.14 Leading Non-Industry Players: Distribution by Number of Pipeline Candidates
Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year 2000-2021
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.7 Leading Players: Distribution by Number of Registered Trials
Figure 6.8 Word Cloud: Key Focus Areas
Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2018-2021
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2018-2021
Figure 7.3 Grant Analysis: Distribution by Funding Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Word Cloud Analysis: Emerging Focus Areas
Figure 7.10 Grant Analysis: Distribution by Study Section Involved
Figure 7.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.12 Popular NIH Departments: Distribution by Number of Grants
Figure 7.13 Prominent Program Officers: Distribution by Number of Grants Awarded
Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants Awarded
Figure 7.16 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Year of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Global HER2 Targeting Therapies Market, 2021-2031 (USD Million)
Figure 9.2 BAT8001 (Bio-Thera Solutions): Sales Forecast, till 2031 (USD Million)
Figure 9.3 ENHERTU® (AstraZeneca): Sales Forecast, till 2031 (USD Million)
Figure 9.4 Gilotrif® (Boehringer Ingelheim): Sales Forecast, till 2031 (USD Million)
Figure 9.5 KADCYLA™ (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.6 Margenza™ (MacroGenics): Sales Forecast, till 2031 (USD Million)
Figure 9.7 RC48 (RemeGen): Sales Forecast, till 2031 (USD Million)
Figure 9.8 Nerlynx™ (Puma Biotechnology): Sales Forecast, till 2031 (USD Million)
Figure 9.9 Perjeta® (Genentech, a Roche’s company): Sales Forecast, till 2031 (USD Million)
Figure 9.10 SYD985 (Byondis): Sales Forecast, till 2031 (USD Million)
Figure 9.11 MOBOCERTINIB (Takeda): Sales Forecast, till 2031 (USD Million)
Figure 9.12 Tukysa® (Seagen): Sales Forecast, till 2031 (USD Million)
Figure 9.13 Tyverb® (Roche): Sales Forecast, till 2031 (USD Million)
Figure 9.14 Vizimpro® (Pfizer): Sales Forecast, till 2031 (USD Million)
Figure 9.15 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Geography (USD Million)
Figure 9.16 HER2 Targeting Therapies Market in North America, 2021-2031 (USD Million)
Figure 9.17 HER2 Targeting Therapies Market in Europe, 2021-2031 (USD Million)
Figure 9.18 HER2 Targeting Therapies Market in Asia Pacific, 2021-2031 (USD Million)
Figure 9.19 HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031 (USD Million)
Figure 9.20 HER2 Targeting Therapies Market in Latin America, 2021-2031 (USD Million)
Figure 9.21 Global HER2 Targeting Therapies Market 2021 and 2031: Distribution by Target Disease Indication (USD Million)
Figure 9.22 HER2 Targeting Therapies Market for Breast Cancer, 2021-2031 (USD Million)
Figure 9.23 HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031 (USD Million)
Figure 9.24 HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031 (USD Million)
Figure 9.25 HER2 Targeting Therapies Market for Lung Cancer, 2021-2031 (USD Million)
Figure 9.26 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Molecule (USD Million)
Figure 9.27 HER2 Targeting Therapies Market for Biologics, 2021-2031 (USD Million)
Figure 9.28 HER2 Targeting Therapies Market for Small Molecules, 2021-2031 (USD Million)
Figure 9.29 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Therapy (USD Million)
Figure 9.30 HER2 Targeting Therapies Market for Monotherapy, 2021-2031 (USD Million)
Figure 9.31 HER2 Targeting Therapies Market for Combination Therapy, 2021-2031 (USD Million)
Figure 9.32 HER2 Targeting Therapies Market for Both, 2021-2031 (USD Million)
Figure 9.33 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Route of Administration (USD Million)
Figure 9.34 HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031 (USD Million)
Figure 9.35 HER2 Targeting Therapies Market for Oral Therapies, 2021-2031 (USD Million)
Figure 10.1 HER2 Targeting Biosimilars: Distribution by Parent Drug
Figure 10.2 HER2 Targeting Biosimilars: Distribution by Phase of Development of Biosimilar
Figure 10.3 HER2 Targeting Biosimilars: Distribution by Target Disease Indication
Figure 10.4 HER2 Targeting Biosimilar Developers: Distribution by Year of Establishment
Figure 10.5 HER2 Targeting Biosimilar Developers: Distribution by Geographical Location
Figure 10.6 HER2 Targeting Biosimilar Developers: Distribution by Company Size and Geographical Location
Figure 11.1 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Commercial Availability of the Test
Figure 11.2 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Assay Technique Used
Figure 11.3 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Corresponding Drug Candidate
Figure 11.4 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Target Disease Indication
Figure 11.5 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Year of Establishment
Figure 11.6 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Company Size
Figure 11.7 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Geographical Location
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Grant Analysis
Figure 12.4 Concluding Remarks: Partnerships and Collaborations
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 HER2 Targeting Therapies: List of Therapies
Table 4.2 HER2 Targeting Therapies: List of Developers
Table 5.1 HER2 Targeting Therapies List of Companies Profiled
Table 5.2 AstraZeneca: Company Snapshot
Table 5.3 Drug Profile: ENHERTU®
Table 5.4 Drug Profile: AZD8931
Table 5.5 Boehringer Ingelheim: Company Snapshot
Table 5.6 Drug Profile: Gilotrif®
Table 5.7 GlaxoSmithKline: Company Snapshot
Table 5.8 Drug Profile: Tyverb®
Table 5.9 Drug Profile: SB719125
Table 5.10 MacroGenics: Company Snapshot
Table 5.11 Drug Profile: MARGENZA™
Table 5.12 Pfizer: Company Snapshot
Table 5.13 Drug Profile: Vizimpro®
Table 5.14 Drug Profile: CP-724714
Table 5.15 Drug Profile: PF-06804103
Table 5.16 Puma Biotechnology: Company Snapshot
Table 5.17 Drug Profile: Nerlynx™
Table 5.18 Roche: Company Snapshot
Table 5.19 Drug Profile: PERJETA®
Table 5.20 Drug Profile: Kadcyla™
Table 5.21 Drug Profile: RG6194
Table 5.22 Drug Profile: BTRC4017A
Table 5.23 Drug Profile: RG6148
Table 5.24 Seagen: Company Snapshot
Table 5.25 Drug Profile: Tukysa®
Table 5.26 Triumvira Immunologics: Company Snapshot
Table 5.27 Drug Profile: TAC01
Table 5.28 Drug Profile: TAC02
Table 5.29 ZymeWorks: Company Snapshot
Table 5.30 Drug Profile: ZW25
Table 5.31 Drug Profile: ZW49

Table 8.1 HER2 Targeting Therapies: List of Partnerships and Collaborations
Table 9.1 HER2 Targeting Therapies: List of Forecasted Therapies
Table 10.1 HER2 Targeting Biosimilars: List of Therapies
Table 10.2 HER2 Targeting Biosimilars: List of Developers
Table 11.1 Companion Diagnostics for HER2 Targeting Therapies: List of Products
Table 11.2 Companion Diagnostics for HER2 Targeting Therapies: List of Developers
Table 13.1 HER2 Targeting Therapies: Distribution by Current Status
Table 13.2 HER2 Targeting Therapies: Distribution by Phase of Development
Table 13.3 HER2 Targeting Therapies: Distribution by Type of Molecule
Table 13.4 HER2 Targeting Therapies: Distribution by Type of Biologic
Table 13.5 HER2 Targeting Therapies: Distribution by Type of Therapy
Table 13.6 HER2 Targeting Therapies: Distribution by Target Disease Indication
Table 13.7 HER2 Targeting Therapies: Distribution by Route of Administration
Table 13.8 HER2 Targeting Therapies Developers: Distribution by Type of Developer
Table 13.9 HER2 Targeting Therapies Developers: Distribution by Year of Establishment
Table 13.10 HER2 Targeting Therapies Developers: Distribution by Company Size
Table 13.11 HER2 Targeting Therapies Developers: Distribution by Geographical Location
Table 13.12 HER2 Targeting Therapies Developers: Distribution by Company Size and Geographical Location
Table 13.13 Leading Industry Players: Distribution by Number of Pipeline Candidates
Table 13.14 Leading Non-Industry Players: Distribution by Number of Pipeline Candidates
Table 13.15 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year 2000-2021
Table 13.16 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.17 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 13.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 13.19 Clinical Trial Analysis: Distribution by Study Design
Table 13.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 13.21 Leading Players: Distribution by Number of Registered Trials
Table 13.22 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 13.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Table 13.24 Popular Indications: Distribution by Number of Registered Trials
Table 13.25 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 13.26 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 13.27 Grant Analysis: Cumulative Trend by Year of Grant Award, 2018-2021
Table 13.28 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2018-2021
Table 13.29 Grant Analysis: Distribution by Funding Institute Center
Table 13.30 Grant Analysis: Distribution by Support Period
Table 13.31 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 13.32 Grant Analysis: Distribution by Type of Grant Application
Table 13.33 Grant Analysis: Distribution by Purpose of Grant Award
Table 13.34 Grant Analysis: Distribution by Activity Code
Table 13.35 Grant Analysis: Distribution by Study Section Involved
Table 13.36 Grant Analysis: Distribution by Type of Recipient Organization
Table 13.37 Popular NIH Departments: Distribution by Number of Grants
Table 13.38 Prominent Program Officers: Distribution by Number of Grants Awarded
Table 13.39 Prominent Program Officers: Distribution by Number of Grants
Table 13.40 Popular Recipient Organizations: Distribution by Number of Grants Awarded
Table 13.41 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 13.42 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Table 13.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.44 Partnerships and Collaborations: Distribution by Type of Partnership and Year of Partnership
Table 13.45 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.46 Partnerships and Collaborations: Distribution by Type of Molecule
Table 13.47 Most Active Players: Distribution by Number of Partnerships
Table 13.48 Partnerships and Collaborations: Regional Distribution
Table 13.49 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.50 Global HER2 Targeting Therapies Market, 2021-2031 (USD Million)
Table 13.51 BAT8001 (Bio-Thera Solutions): Sales Forecast, till 2031 (USD Million)
Table 13.52 ENHERTU® (AstraZeneca): Sales Forecast, till 2031 (USD Million)
Table 13.53 Gilotrif® (Boehringer Ingelheim): Sales Forecast, till 2031 (USD Million)
Table 13.54 KADCYLA™ (Roche): Sales Forecast, till 2031 (USD Million)
Table 13.55 Margenza™ (MacroGenics): Sales Forecast, till 2031 (USD Million)
Table 13.56 RC48 (RemeGen): Sales Forecast, till 2031 (USD Million)
Table 13.57 Nerlynx™ (Puma Biotechnology): Sales Forecast, till 2031 (USD Million)
Table 13.58 Perjeta® (Genentech, a Roche’s company): Sales Forecast, till 2031 (USD Million)
Table 13.59 SYD985 (Byondis): Sales Forecast, till 2031 (USD Million)
Table 13.60 MOBOCERTINIB (Takeda): Sales Forecast, till 2031 (USD Million)
Table 13.61 Tukysa® (Seagen): Sales Forecast, till 2031 (USD Million)
Table 13.62 Tyverb® (Roche): Sales Forecast, till 2031 (USD Million)
Table 13.63 Vizimpro® (Pfizer): Sales Forecast, till 2031 (USD Million)
Table 13.64 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Geography (USD Million)
Table 13.65 HER2 Targeting Therapies Market in North America, 2021-2031 (USD Million)
Table 13.66 HER2 Targeting Therapies Market in Europe, 2021-2031 (USD Million)
Table 13.67 HER2 Targeting Therapies Market in Asia Pacific, 2021-2031 (USD Million)
Table 13.68 HER2 Targeting Therapies Market in Middle East and North Africa, 2021-2031 (USD Million)
Table 13.69 HER2 Targeting Therapies Market in Latin America, 2021-2031 (USD Million)
Table 13.70 Global HER2 Targeting Therapies Market 2021 and 2031: Distribution by Target Disease Indication (USD Million)
Table 13.71 HER2 Targeting Therapies Market for Breast Cancer, 2021-2031 (USD Million)
Table 13.72 HER2 Targeting Therapies Market for Gastric Cancer, 2021-2031 (USD Million)
Table 13.73 HER2 Targeting Therapies Market for Head and Neck Cancer, 2021-2031 (USD Million)
Table 13.74 HER2 Targeting Therapies Market for Lung Cancer, 2021-2031 (USD Million)
Table 13.75 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Molecule (USD Million)
Table 13.76 HER2 Targeting Therapies Market for Biologics, 2021-2031 (USD Million)
Table 13.77 HER2 Targeting Therapies Market for Small Molecules, 2021-2031 (USD Million)
Table 13.78 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Type of Therapy (USD Million)
Table 13.79 HER2 Targeting Therapies Market for Monotherapy, 2021-2031 (USD Million)
Table 13.80 HER2 Targeting Therapies Market for Combination Therapy, 2021-2031 (USD Million)
Table 13.81 HER2 Targeting Therapies Market for Both, 2021-2031 (USD Million)
Table 13.82 Global HER2 Targeting Therapies Market, 2021 and 2031: Distribution by Route of Administration (USD Million)
Table 13.83 HER2 Targeting Therapies Market for Intravenous Therapies, 2021-2031 (USD Million)
Table 13.84 HER2 Targeting Therapies Market for Oral Therapies, 2021-2031 (USD Million)
Table 13.85 HER2 Targeting Biosimilars: Distribution by Parent Drug
Table 13.86 HER2 Targeting Biosimilars: Distribution by Phase of Development of Biosimilar
Table 13.87 HER2 Targeting Biosimilars: Distribution by Target Disease Indication
Table 13.88 HER2 Targeting Biosimilar Developers: Distribution by Year of Establishment
Table 13.89 HER2 Targeting Biosimilar Developers: Distribution by Geographical Location
Table 13.90 HER2 Targeting Biosimilar Developers: Distribution by Company Size and Geographical Location
Table 13.91 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Commercial Availability of the Test
Table 13.92 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Assay Technique Used
Table 13.93 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Corresponding Drug Candidate
Table 13.94 Companion Diagnostics for HER2 Targeting Therapies: Distribution by Target Disease Indication
Table 13.95 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Year of Establishment
Table 13.96 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Company Size
Table 13.97 Companion Diagnostics for HER2 Targeting Therapies: Distribution of Developers by Geographical Location

 

List Of Companies

The following companies and organizations have been mentioned in the report.

1. Abbott
2. AbbVie
3. Acepodia
4. AdaptVac
5. Advaxis
6. Affimed
7. Agilent Technologies
8. Aleta Biotherapeutics
9. Alphamab Oncology
10. AlphaVax
11. Alpine Immune Sciences
12. Alteogen
13. Ambrx
14. Amgen
15. Amunix
16. Anhui Anke Biotechnology
17. Apotex
18. Artiva Biotherapeutics
19. AryoGen Pharmed
20. AstraZeneca
21. Aurora Biopharma
22. Barbara Ann Karmanos Cancer Institute
23. Bavarian Nordic
24. Bayer
25. Baylor College of Medicine
26. BeiGene
27. Beijing Mabworks Biotech
28. Bellicum Pharmaceuticals
29. BioAtla
30. BIOCAD
31. Biocon
32. Biocytogen
33. BioGenex
34. Bio-Thera Solutions
35. BioXpress Therapeutics
36. Black Diamond Therapeutics
37. Bliss Biopharmaceutical
38. bluebird bio
39. Boehringer Ingelheim
40. Bolt Biotherapeutics
41. BrightPath Biotherapeutics
42. Bristol-Myers Squibb
43. Byondis (formerly Synthon Biopharmaceuticals)
44. CARISMA Therapeutics
45. Case Western Reserve University
46. Catalent
47. Celcuity
48. Celgene
49. Cellid
50. Celltrion Healthcare
51. CEVEC Pharmaceuticals
52. CinnaGen
53. City of Hope National Medical Center
54. Covance
55. CSPC Pharmaceutical
56. Curis
57. Daiichi Sankyo
58. Dana-Farber Cancer Institute
59. Denali Therapeutics
60. Dizal Pharmaceuticals
61. DM Bio
62. DotBio
63. Dr. Reddy's Laboratories
64. Dragonfly Therapeutics
65. Duke University
66. EirGenix
67. Eli Lilly
68. Etubics
69. Evergreen Theragnostics
70. Exelixis
71. ExpreS2ion Biotechnologies
72. F1 Oncology
73. Fochon Pharmaceuticals
74. Fosun Pharmaceutical
75. Foundation Medicine
76. Fudan University
77. Genentech
78. GeneQuantum Healthcare
79. Genor Biopharma
80. GlaxoSmithKline
81. Glenmark Pharmaceuticals
82. Goethe University Frankfurt
83. Guardant Health
84. H. Lee Moffitt Cancer Center and Research Institute
85. Hanmi Pharmaceutical
86. Harbour BioMed
87. Heidelberg Pharma
88. Helixmith
89. Henlius Biotech
90. HLB Life Science
91. ImmuneOnco Biopharmaceuticals
92. Imugene
93. Indiana University
94. InNexus Biotechnology
95. Innovent Biologics
96. Intas Pharmaceuticals
97. Jiangsu Hengrui Medicine
98. Johns Hopkins University
99. Johnson & Johnson
100. Juniper Pharmaceuticals
101. JW Therapeutics
102. Kadmon
103. KLUS Pharma
104. Knight Therapeutics
105. Laboratoires Pierre Fabre
106. LegoChem Biosciences
107. Leica Biosystems
108. LEO Pharma
109. LinXis
110. Lonza
111. Lupin
112. Mabpharm
113. MabSpace Biosciences
114. MacroGenics
115. Marker Therapeutics
116. Mayo Clinic
117. Memorial Sloan Kettering Cancer Center
118. Merck
119. Mersana Therapeutics
120. Merus
121. MilliporeSigma
122. Molecular Partners
123. Molecular Templates
124. Morphotek
125. Mustang Bio
126. National Cancer Institute (NCI)
127. NBE Therapeutics
128. NeuClone
129. Nipro
130. Novartis Pharmaceuticals
131. NYU Langone Health
132. Ohio State University
133. OncoQR
134. ORIC Pharmaceuticals
135. OS Therapies (OST)
136. Palleon Pharmaceuticals
137. Parker Institute for Cancer Immunotherapy
138. Pfizer
139. Phio Pharmaceuticals
140. Pieris Pharmaceuticals
141. Precirix
142. Prescient Therapeutics
143. Prestige BioPharma
144. Puma Biotechnology
145. PX'Therapeutics
146. QIAGEN
147. RemeGen
148. Roche
149. Samsung Bioepis
150. San Antonio Military Medical Center (SAMMC)
151. Sanofi
152. Seattle Genetics
153. Second Affiliated Hospital of Guangzhou Medical University
154. Shanghai Henlius Biotech
155. Shanghai Miracogen
156. Shanghai PerHum Therapeutics
157. Shanghai Pharmaceuticals
158. Shenzhen Geno-immune Medical Institute
159. Shinshu University 
160. Silverback Therapeutics
161. Sinobioway
162. Spectrum Pharmaceuticals
163. Sun Yat-sen University
164. Synaffix
165. Taiho Oncology
166. Takeda
167. Tanvex BioPharma
168. TC BioPharm
169. Technical University of Munich
170. Tessa Therapeutics
171. Tevogen Bio
172. Thermo Fisher Scientific
173. Trinity College London
174. Triumvira Immunologics
175. UBiome
176. United BioPharma
177. University Hospital Brussels
178. University of California
179. University of Minnesota
180. University of North Carolina
181. University of Pennsylvania
182. University of Texas
183. University of Toronto 
184. University of Washington
185. UWELL Biopharma
186. Vineti
187. VIVEbiotech
188. Voronoi 
189. Xyphos Biosciences
190. YZY Biopharma
191. Zion Pharma
192. Zymeworks